These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28744159)

  • 21. Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials.
    Wang L; Xu YL; Zhang XQ
    Leuk Lymphoma; 2014 Jul; 55(7):1479-88. PubMed ID: 23998282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis.
    Cao Y; Wan N; Liang Z; Xie J; Wang S; Lin T; Zhang T; Jiang J
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e478-e488. PubMed ID: 31130487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and toxicity of carfilzomib- or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta-analysis.
    Xie C; Wei M; Yang F; Liu Q; Wu F; Huang J
    Medicine (Baltimore); 2022 Sep; 101(39):e30715. PubMed ID: 36181088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials.
    Li JL; Fan GY; Liu YJ; Zeng ZH; Huang JJ; Yang ZM; Meng XY
    Front Pharmacol; 2018; 9():430. PubMed ID: 29760659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.
    Ludwig H; Greil R; Masszi T; Spicka I; Shpilberg O; Hajek R; Dmoszynska A; Paiva B; Vidriales MB; Esteves G; Stoppa AM; Robinson D; Chaturvedi S; Ataman O; Enny C; Feng H; van de Velde H; Viterbo L
    Br J Haematol; 2015 Nov; 171(3):344-54. PubMed ID: 26153365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
    Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
    Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy and safety of CTD and PCD regimens in treatment of patients with newly diagnosed multiple myeloma].
    Gu Y; Yuan YH; Shi QL; Qu XY; Xu J; Guo R; Xu JD; Li JY; Chen LJ
    Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):279-284. PubMed ID: 28468087
    [No Abstract]   [Full Text] [Related]  

  • 28. Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma.
    Dolph M; Tremblay G; Gilligan AM; Leong H
    J Health Econ Outcomes Res; 2021; 8(2):26-35. PubMed ID: 34616855
    [No Abstract]   [Full Text] [Related]  

  • 29. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
    Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
    Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency].
    An N; Li X; Shen M; Chen SL; Huang ZX
    Zhonghua Nei Ke Za Zhi; 2016 Oct; 55(10):764-768. PubMed ID: 27686436
    [No Abstract]   [Full Text] [Related]  

  • 32. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
    Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation.
    Weisel K; Doyen C; Dimopoulos M; Yee A; Lahuerta JJ; Martin A; Travers K; Druyts E; Toor K; Abildgaard N; Lu J; Van Droogenbroeck J; Geraldes C; Petrini M; Voillat L; Voog E; Facon T
    Leuk Lymphoma; 2017 Jan; 58(1):153-161. PubMed ID: 27124703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
    Huang H; Zhou L; Peng L; Fu W; Zhang C; Hou J
    Leuk Res; 2014 Sep; 38(9):1048-54. PubMed ID: 25052306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
    Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
    Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang L; Ran X; Wang B; Sheng Z; Liu L
    Hematol Oncol; 2012 Jun; 30(2):57-61. PubMed ID: 21809367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan.
    Du JS; Kuo YC; Shi HY; Wang MC; Wang LY; Chuang TM; Ke YL; Yeh TJ; Gau YC; Wang HC; Cho SF; Hsiao SY; Liu YC; Hsu CM; Hsiao HH
    J Pers Med; 2022 Jan; 12(2):. PubMed ID: 35207619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
    Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
    Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy.
    Weisel K; Wadlund AO; Gungor G; Dergarabetian E; Pacheco C; Masurkar N; Rodriguez-Otero P
    Eur J Haematol; 2022 Oct; 109(4):388-397. PubMed ID: 35775385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.